<DOC>
	<DOCNO>NCT00620295</DOCNO>
	<brief_summary>RATIONALE : Bortezomib may stop growth solid tumor block enzymes need cell growth block blood flow tumor . Drugs use chemotherapy , gemcitabine , work different way stop growth tumor cell , either kill cell stop divide . Giving bortezomib together gemcitabine may kill tumor cell . PURPOSE : This phase I trial study side effect best dose bortezomib gemcitabine treat old patient advance solid tumor .</brief_summary>
	<brief_title>Bortezomib Gemcitabine Treating Older Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine maximum tolerate dose weekly bortezomib gemcitabine treat elderly patient advance solid tumor . Secondary - To characterize quantitative qualitative toxicity bortezomib gemcitabine patient . - To obtain preliminary information anti-tumor activity bortezomib gemcitabine . - To characterize gemcitabine metabolite pharmacokinetics patient receive concurrent bortezomib therapy . OUTLINE : This phase I dose escalation study bortezomib gemcitabine . Patients receive gemcitabine intravenously ( IV ) 30 minute follow 1 hour later bortezomib IV 3-5 second day 1 8 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos gemcitabine bortezomib maximum tolerate dose combination determine . Blood collect periodically pharmacokinetic pharmacogenetic study . After completion study treatment , patient follow every 3 month 1 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis advance nonhematologic malignancy , include follow : Breast cancer Lung cancer Colon cancer Pancreatic cancer Head neck cancer Sarcoma Must fail become intolerant prior standard therapy longer likely respond therapy ( disease except pancreatic cancer ) Pancreatic cancer patient may enrol prior therapy requirement since gemcitabine current standard care 1st line therapy Measurable nonmeasurable disease Concurrent enrollment University Minnesota study `` Population Pharmacokinetics Pharmacogenetics Gemcitabine Adult Patients Solid Tumors '' ( Human Subjects Code 0508M72989 ) require ECOG performance status 01 Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 10 g/dL Bilirubin ≤ 1.5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 3.0 time ULN ( 5 time ULN liver tumor involvement ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 3.0 time ULN ( 5 time ULN liver tumor involvement ) Calculated measured creatinine clearance &gt; 30 mL/minute Fertile patient must use effective contraception 3 month study participation Recovered prior therapy Prior systemic chemotherapy , immunotherapy , biological therapy allow At least 3 month since prior bortezomib and/or gemcitabine At least 2 week since prior systemic therapy At least 3 week since prior investigational agent ( reason treatment cancer ) At least 2 week since prior radiotherapy Symptomatic brain metastasis Serious concomitant medical psychiatric disorder ( e.g. , active infection uncontrolled diabetes ) , opinion investigator , would compromise safety patient compromise patient 's ability complete study Myocardial infarction within past 6 month New York Heart Association ( NYHA ) Class III IV heart failure Uncontrolled angina Severe uncontrolled ventricular arrhythmia Electrocardiographic evidence acute ischemia active conduction system abnormalities Peripheral neuropathy ≥ grade 2 Known hypersensitivity bortezomib , boron mannitol Prior radiotherapy ≥ 25 % bone marrow Prior radiotherapy whole pelvis Concurrent filgrastim ( GCSF ) hematologic support course 1 study treatment</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>recurrent small cell lung cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>recurrent head neck cancer</keyword>
	<keyword>ovarian cancer</keyword>
	<keyword>recurrent uterine cancer</keyword>
	<keyword>recurrent kidney cancer</keyword>
	<keyword>recurrent osteosarcoma</keyword>
</DOC>